Clinical-stage · broad-spectrum antiviral platform

One Molecule.
Four Therapeutic Pillars.

Ranpirnase is a host-directed ribonuclease with broad-spectrum antiviral activity — virus- and strain-agnostic, therapeutic and prophylactic, with more than 1,000 patients dosed to date.

Pink Eye Comes First

Acute infectious conjunctivitis is where a broad-spectrum antiviral proves itself fastest: a large indication, a clear viral cause, no approved therapy and a readout measured in days.

Success in the eye would provide human validation of the mechanism and generate clinical experience that may inform development across the broader platform.

1000+

Patients dosed to date by intravenous, topical ophthalmic and dermal delivery, with an excellent safety profile.

23

Viruses with significant selectivity indices, tested independently by USAMRIID, NIAID, the CDC and Utah State University.

2042

Latest patent expiry in a layered estate covering composition, use and prophylaxis.

Clinical-stage · broad-spectrum antiviral platform

One mechanism, carried across four therapeutic pillars

Ophthalmology

Acute infectious conjunctivitis (Treyegen™), HSV keratitis and CMV retinitis.

Preserve Vision.
Save Lives

Medical Countermeasures

Ebola, Marburg, Sudan and Nipah, being evaluated for potential development with government agencies.

Prepare Today.
Protect Tomorrow.

Systemic Antivirals

Influenza A/B, RSV, adenovirus, rhinovirus and COVID-19 in intranasal and inhaled formulations.

Broad Protection
For a Wider World

Dermatology

HPV genital warts with positive Phase IIa data, and HSV lesions with positive Phase I.

Targeted Solutions
For Persistent Viral Disease

Where We Are

EMERALD cleared to begin, with clinical
development advancing in 2026

EMERALD is a Phase 1/2 study of OKG-0303 in acute infectious conjunctivitis, designed to evaluate safety, tolerability and antiviral activity in a real-world patient population.

Completed

India IND Cleared

Clearance to enroll subjects in EMERALD Phase ½

In Progress

Clinical Supply in Manufacture

Formulation and stability complete; clinical manufacturing in progress.

Up Next

EMERALD Phase 1/2

A seamless study of OKG-0303 in acute infectious conjunctivitis.

Future Milestone

Initial Clinical Data

Targeted for Q4 2026, subject to enrollment and study progress.

Clinical-stage · broad-spectrum antiviral platform

One Molecule.
Four Therapeutic Pillars.

Pink Eye Comes First

1000+

23

2042

Clinical-stage · broad-spectrum antiviral platform